Bill Text: TX HB1802 | 2021-2022 | 87th Legislature | Comm Sub

NOTE: There are more recent revisions of this legislation. Read Latest Draft

---

Bill Title: Relating to a study on the use of alternative therapies for treating post-traumatic stress disorder.

Spectrum: Bipartisan Bill

Status: (Passed) 2021-06-18 - Effective immediately [HB1802 Detail]

Download: Texas-2021-HB1802-Comm_Sub.html

---

By: Dominguez, et al. H.B. No. 1802
(Senate Sponsor - Campbell, et al.)
(In the Senate - Received from the House May 10, 2021;
May 17, 2021, read first time and referred to Committee on Veteran
Affairs & Border Security; May 19, 2021, reported favorably by the
following vote: Yeas 6, Nays 0; May 19, 2021, sent to printer.)
Click here to see the committee vote

A BILL TO BE ENTITLED
AN ACT
relating to a study on the use of alternative therapies for treating
post-traumatic stress disorder.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1. (a) In this Act, "commission" means the Health
and Human Services Commission.
(b) The commission, in collaboration with Baylor College of
Medicine and in partnership with a military veterans hospital or a
medical center that provides medical care to veterans, shall
conduct a study on the efficacy of using alternative therapies,
including the use of 3,4-methylenedioxymethamphetamine (MDMA),
psilocybin, and ketamine, in the treatment of veterans who suffer
from post-traumatic stress disorder.
(c) In conducting the study described by Subsection (b) of
this section, the commission in collaboration with the Baylor
College of Medicine shall:
(1) perform a clinical trial on the therapeutic
efficacy of using psilocybin in the treatment of
treatment-resistant post-traumatic stress disorder in veterans;
and
(2) review current literature regarding:
(A) the safety and efficacy of
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and
ketamine in the treatment of post-traumatic stress disorder; and
(B) the access veterans have to
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and
ketamine for treatment of post-traumatic stress disorder in the
United States.
(d) The commission shall prepare and submit to the governor,
the lieutenant governor, the speaker of the house of
representatives, and each member of the legislature:
(1) quarterly reports on the progress of the study
conducted under this section; and
(2) not later than December 1, 2024, a written report
containing the results of the study conducted under this section
and any recommendations for legislative or other action.
(e) The commission shall ensure any protected health
information collected during a clinical trial conducted under
Subsection (c) of this section and reported under Subsection (d) of
this section does not personally identify an individual.
(f) This Act expires September 1, 2025.
SECTION 2. This Act takes effect immediately if it receives
a vote of two-thirds of all the members elected to each house, as
provided by Section 39, Article III, Texas Constitution. If this
Act does not receive the vote necessary for immediate effect, this
Act takes effect September 1, 2021.
* * * * *